Is CLBT a good stock to buy? We came across a bullish thesis on Cellebrite DI Ltd. on InfoArb Sheets’s Substack. In this article, we will summarize the bulls’ thesis on CLBT. Cellebrite DI Ltd.’s share was trading at $12.47 as of June 17th. CLBT’s trailing and forward P/E were 45.75 and 35.71 respectively according to Yahoo Finance.
Copyright: welcomia / 123RF Stock Photo
Cellebrite DI Ltd. develops software and services for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. CLBT is positioning itself for a new phase of growth as it evolves from a leading digital forensics provider into a broader AI-powered investigative intelligence platform. The company serves more than 7,000 law enforcement agencies, defense organizations, intelligence services, and enterprises, helping customers access, analyze, manage, and preserve digital evidence across mobile devices, computers, drones, cloud environments, and other data sources.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Q1 2026 demonstrated strong operational momentum, with revenue increasing 19% year over year to $128.3 million, subscription revenue rising 23%, Annual Recurring Revenue growing 21%, and a trailing twelve-month free cash flow margin of 32%, highlighting the strength of its recurring software model. Management emphasized that the company is still in the early stages of a broader growth acceleration driven by Genesis AI, Advanced Unlock capabilities, federal cloud adoption, drone forensics, and expanded platform sales.
A key element of the bullish thesis is that current guidance assumes no meaningful AI-specific revenue contribution, creating potential upside if Genesis AI converts its more than 500 early registered users into paying customers following general availability. Cellebrite has also secured FedRAMP High Authorization, strengthening its position in the U.S. federal market where the pipeline has already grown 35% year over year after a subdued 2025.
Meanwhile, growth products including Guardian, Pathfinder, Corellium, and drone forensics doubled year over year and are expected to represent an increasingly meaningful share of ARR. As larger federal and defense contracts emerge and AI expands the company’s reach beyond forensic examiners to detectives, investigators, and prosecutors, Cellebrite has an opportunity to increase wallet share, accelerate ARR growth, and establish itself as the leading end-to-end investigative intelligence platform.
Previously, we covered a bullish thesis on Axon Enterprise, Inc. (AXON) by RadnorCapital in March 2025, which highlighted the company’s sustained 30%+ growth, expanding opportunities across international, federal, and enterprise markets, and growing adoption of AI, drones, and robotics. AXON’s stock price has depreciated by approximately 15.28% since our coverage. InfoArb Sheets shares a similar view but emphasizes on Cellebrite’s AI-driven investigative intelligence platform, federal cloud adoption, and digital forensics expansion.
Cellebrite DI Ltd. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 36 hedge fund portfolios held CLBT at the end of the first quarter which was 35 in the previous quarter. While we acknowledge the risk and potential of CLBT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CLBT and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
